|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||21.00 - 21.00|
|52 Week Range||16.00 - 29.00|
|Beta (3Y Monthly)||8.07|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Phoenix Life Sciences International Limited (PLSI) (“Phoenix Life”), an international adaptive healthcare solutions company, today announced that it is now accepting bids from U.S. licensed producers of industrial hemp to supply various products to be used in the formulation of its botanical pharmaceuticals. “As we move forward with our mission of transforming the future of global healthcare, our next step is partnering with a GMP licensed hemp producers in the U.S. that shares our values and mission to push botanical pharmaceuticals forward throughout the world,” said Phoenix Life CEO Martin Tindall. Phoenix Life is seeking a Good Manufacturing Practice (GMP) licensed industrial hemp partner for both U.S. and foreign markets to commence in January 2019.
Phoenix Life Sciences International Limited (PLSI) (“Phoenix Life”), an international adaptive healthcare solutions company, today announced that it has released an online version of its Investor Relations deck with an accompanying video presentation on its website and at http://phxlife.net/PLSI-Deck. During the presentation video, Phoenix Life CEO Martin Tindall walks prospective investors through the company’s background, overall mission, business model, future plans and information on how to invest in Phoenix Life’s goal of transforming the future of global healthcare. “We are excited to release our Investor Relations deck and video presentation on our company website to provide investors in the public markets with a clear understanding of the business of Phoenix Life, our mission and our objectives,” said Phoenix Life Sciences International CEO Martin Tindall.
Phoenix Life Sciences International Limited (PLSI) (“Phoenix Life”), an international adaptive healthcare solutions company, today announced that Angus Stewart has joined the company as the Agriculture and Horticulture Senior Advisor. Angus Stewart has over two decades of experience specializing in horticulture and is currently an Agricultural and Horticultural Scientist and Consultant Plant Breeder of approximately 100 commercially released plant cultivars. Additionally, Stewart has extensive experience with plant breeding techniques of all levels and is well versed in the best practices for the production and extraction of botanical active ingredients like cannabinoids.
Phoenix Life Sciences International Limited (PLSI) (“Phoenix Life”), an international adaptive healthcare solutions company, today announced that it has received an import certificate from the Republic of Vanuatu’s Minister of Health to bring its cannabis diabetes drug Phoenix Metabolic into the country for clinical trials. “With this certificate, we look forward to playing a pivotal role in decreasing the size of the global diabetes epidemic,” said Phoenix Life Sciences International CEO Martin Tindall. Phoenix Life can now import its cannabis-based diabetes drug into Vanuatu and the company hopes to soon announce the launch of clinical trials for its first 1,000 patients.
Phoenix Life Sciences International Limited (“Phoenix Life”) (PLSI), an international adaptive healthcare solutions company, today announced that it has retired additional convertible debt, positioning the company with no more outstanding preferred shares or debt that is subject to conversion. As a part of the implementation of its fiscal policy aimed at bringing shareholders value and forwarding the company's mission of creating a global platform for plant-based pharmaceuticals, including bringing medical cannabis products into the mainstream of healthcare, the company has retired its outstanding Series C debt and canceled its Series A and B. “To operate under the umbrella company Phoenix Life Sciences International, we executed the consolidation of various entities and focused on eliminating as much expensive debt as possible,” said Martin Tindall, Chief Executive Officer of Phoenix Life Sciences International.